111 related articles for article (PubMed ID: 23047832)
1. Evaluation of the prognostic meaning of C-reactive protein (CRP) in children and adolescents with classical Hodgkin's lymphoma (HL).
Haase R; Vilser C; Mauz-Körholz C; Hasenclever D; Kluge R; Ruschke K; Borkhardt A; Seeger K; Lehrnbecher T; Kulozik A; Rößler J; Burdach S; Jürgens H; Körholz D
Klin Padiatr; 2012 Oct; 224(6):377-81. PubMed ID: 23047832
[TBL] [Abstract][Full Text] [Related]
2. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.
Bien E; Balcerska A
Scand J Immunol; 2009 Nov; 70(5):490-500. PubMed ID: 19874554
[TBL] [Abstract][Full Text] [Related]
3. C-reactive protein (CRP) as tumor marker in pediatric and adolescent patients with Hodgkin disease.
Wieland A; Kerbl R; Berghold A; Schwinger W; Mann G; Urban C
Med Pediatr Oncol; 2003 Jul; 41(1):21-5. PubMed ID: 12764738
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of erythrocyte sedimentation rate, C-reactive protein and serum lactate dehydrogenase levels in the diagnosis, prognosis and treatment monitoring of children suffering from cancer].
Bień E; Balcerska A
Med Wieku Rozwoj; 2004; 8(4 Pt 2):1081-9. PubMed ID: 15951603
[TBL] [Abstract][Full Text] [Related]
5. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma.
Vassilakopoulos TP; Nadali G; Angelopoulou MK; Siakantaris MP; Dimopoulou MN; Kontopidou FN; Karkantaris C; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Pizzolo G; Pangalis GA
Haematologica; 2002 Jul; 87(7):701-8; discussion 708. PubMed ID: 12091120
[TBL] [Abstract][Full Text] [Related]
7. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis.
Visco C; Nadali G; Vassilakopoulos TP; Bonfante V; Viviani S; Gianni AM; Federico M; Luminari S; Peethambaram P; Witzig TE; Pangalis G; Cabanillas F; Medeiros LJ; Sarris AH; Pizzolo G
Eur J Haematol; 2006 Nov; 77(5):387-94. PubMed ID: 16879607
[TBL] [Abstract][Full Text] [Related]
8. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
9. Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients.
Akhtar S; El Weshi A; Abdelsalam M; Hussaini H; Janabi I; Rahal M; Maghfoor I
Bone Marrow Transplant; 2007 Oct; 40(7):651-8. PubMed ID: 17660837
[TBL] [Abstract][Full Text] [Related]
10. Lymphocyte-depleted classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin study group.
Klimm B; Franklin J; Stein H; Eichenauer DA; Haverkamp H; Diehl V; Fuchs M; Borchmann P; Engert A
J Clin Oncol; 2011 Oct; 29(29):3914-20. PubMed ID: 21911729
[TBL] [Abstract][Full Text] [Related]
11. [Primary-refractory forms of Hodgkin's lymphoma].
Filatova LV; Tarasenkova AA; Gershanovich ML; Semiglazova TIu
Vopr Onkol; 2012; 58(5):627-38. PubMed ID: 23600279
[TBL] [Abstract][Full Text] [Related]
12. [Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases].
Tan WY; Hu DS; Zeng FY; Song QB; Hu S; Wei L; Zhou LQ
Ai Zheng; 2007 Dec; 26(12):1360-4. PubMed ID: 18076802
[TBL] [Abstract][Full Text] [Related]
13. [Influence of age on treatment results in children and adolescents with Hodgkin's disease].
Balwierz W; Moryl-Bujakowska A; Depowska T; Klekawka T; Stanuch H; Matysiak M; Sopyło B; Kołakowska-Mrozowska B; Krenke K; Chybicka A; Raś M; Sońta-Jakimczyk D; Moszant A; Wachowiak J; Kaczmarek-Kanold M; Kowalczyk J; Odój T; Balcerska A; Drozyńska E; Wysocki M; Kołtan A; Krawczuk-Rybak M; Stolarska M
Przegl Lek; 2004; 61 Suppl 2():40-4. PubMed ID: 15686044
[TBL] [Abstract][Full Text] [Related]
14. [A retrospective analysis of the treatment results in Hodgkin's disease in a radiotherapy clinic].
Mjaaland I; Ganser D; Freitag EM; Bohndorf W
Strahlenther Onkol; 1994 Sep; 170(9):516-23. PubMed ID: 7524173
[TBL] [Abstract][Full Text] [Related]
15. Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades.
Koumarianou AA; Xiros N; Papageorgiou E; Pectasides D; Economopoulos T
Anticancer Res; 2007; 27(2):1191-7. PubMed ID: 17465262
[TBL] [Abstract][Full Text] [Related]
16. Circulating immune complexes in advanced Hodgkin's disease: qualitative analysis and prognostic significance.
Tomasević Z; Jelić S
Arch Immunol Ther Exp (Warsz); 2000; 48(3):195-200. PubMed ID: 10912625
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of erythrocyte sedimentation rate and C-reactive protein in the blood of patients with glioma.
Strojnik T; Smigoc T; Lah TT
Anticancer Res; 2014 Jan; 34(1):339-47. PubMed ID: 24403485
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of pretreatment serum C-reactive protein level in soft tissue sarcoma.
Nakamura T; Matsumine A; Matsubara T; Asanuma K; Uchida A; Sudo A
Cancer; 2012 Feb; 118(4):1055-61. PubMed ID: 21761398
[TBL] [Abstract][Full Text] [Related]
19. Longer failure-free survival interval of Epstein-Barr virus-associated classical Hodgkin's lymphoma: a single-institution study.
Krugmann J; Tzankov A; Gschwendtner A; Fischhofer M; Greil R; Fend F; Dirnhofer S
Mod Pathol; 2003 Jun; 16(6):566-73. PubMed ID: 12808062
[TBL] [Abstract][Full Text] [Related]
20. Hodgkin's lymphoma in adolescents.
Foltz LM; Song KW; Connors JM
J Clin Oncol; 2006 Jun; 24(16):2520-6. PubMed ID: 16735704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]